Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.16 -1.6%	$2.91	$2.46 ▼ $4.15	$270.43M	0.18	316,505 shs	340,714 shs
CRVS Corvus Pharmaceuticals	$4.19 -1.2%	$3.60	$1.75 ▼ $10.00	$285.63M	0.57	768,088 shs	763,117 shs
VNDA Vanda Pharmaceuticals	$4.51 -2.6%	$4.32	$3.81 ▼ $6.63	$265.79M	0.66	638,746 shs	361,867 shs
ZYNE Zynerba Pharmaceuticals	$1.30	$1.30	$0.25 ▼ $1.40	$70.12M	1.32	515,333 shs	N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	-0.63%	+15.33%	+0.96%	-12.47%
CRVS Corvus Pharmaceuticals	0.00%	+7.16%	+16.07%	-11.23%	+105.39%
VNDA Vanda Pharmaceuticals	0.00%	-2.17%	+8.41%	-11.22%	-27.72%
ZYNE Zynerba Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	3.3474 of 5 stars	3.3	4.0	0.0	0.0	2.7	2.5	1.3
CRVS Corvus Pharmaceuticals	2.6539 of 5 stars	3.5	2.0	0.0	0.0	2.7	2.5	0.6
VNDA Vanda Pharmaceuticals	4.6114 of 5 stars	3.8	2.0	0.0	4.2	3.3	3.3	1.3
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	89.87% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	258.00% Upside
VNDA Vanda Pharmaceuticals	3.50	Strong Buy	$16.50	265.85% Upside
ZYNE Zynerba Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZYNE, CRVS, AVIR, and VNDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/14/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$13.00
5/13/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
5/7/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/11/2025	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.20 ➝ $6.00
4/1/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/26/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$14.00 ➝ $15.00
3/26/2025	CRVS Corvus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$6.65 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
VNDA Vanda Pharmaceuticals	$201.35M	1.32	N/A	N/A	$9.23 per share	0.49
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$135.96M	-$1.65	N/A	N/A	N/A	N/A	-34.90%	-32.38%	8/6/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$27.03M	-$0.98	N/A	N/A	N/A	N/A	-70.71%	-45.90%	8/5/2025 (Estimated)
VNDA Vanda Pharmaceuticals	-$18.90M	-$0.75	N/A	N/A	N/A	-9.51%	-3.49%	-2.90%	7/30/2025 (Estimated)
ZYNE Zynerba Pharmaceuticals	-$35.04M	-$0.80	N/A	N/A	N/A	N/A	-90.03%	-72.62%	N/A

Latest ZYNE, CRVS, AVIR, and VNDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AVIR Atea Pharmaceuticals	-$0.56	-$0.40	+$0.16	-$0.40	N/A	N/A
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
5/7/2025	Q1 2025	VNDA Vanda Pharmaceuticals	-$0.55	-$0.50	+$0.05	-$0.50	$45.13 million	$50.04 million
3/25/2025	Q4 2024	CRVS Corvus Pharmaceuticals	-$0.12	-$0.18	-$0.06	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.33	19.33
CRVS Corvus Pharmaceuticals	N/A	0.92	0.92
VNDA Vanda Pharmaceuticals	N/A	4.39	4.37
ZYNE Zynerba Pharmaceuticals	N/A	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
CRVS Corvus Pharmaceuticals	46.64%
VNDA Vanda Pharmaceuticals	88.14%
ZYNE Zynerba Pharmaceuticals	11.23%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
CRVS Corvus Pharmaceuticals	28.50%
VNDA Vanda Pharmaceuticals	10.00%
ZYNE Zynerba Pharmaceuticals	13.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	85.58 million	69.43 million	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	44.15 million	Optionable
VNDA Vanda Pharmaceuticals	290	58.93 million	53.13 million	Optionable
ZYNE Zynerba Pharmaceuticals	25	53.94 million	46.91 million	Optionable

ZYNE, CRVS, AVIR, and VNDA Headlines

Recent News About These Companies

Harmony Biosciences: If It Ain't Broke

June 5, 2025 | seekingalpha.com

US Penny Stocks To Watch In October 2024

October 28, 2024 | uk.finance.yahoo.com

Discover 3 US Penny Stocks With Market Caps Over $70M

October 24, 2024 | uk.finance.yahoo.com

Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight

October 22, 2024 | uk.finance.yahoo.com

GW Pharma's cannabis-derived epilepsy drug approved in EU

October 7, 2024 | pharmaphorum.com

Fragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery Partners

July 31, 2024 | globenewswire.com

Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results

October 31, 2023 | finance.yahoo.com

Why Shares of Harmony Bioscience Are Falling on Friday

October 13, 2023 | fool.com

New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies

October 11, 2023 | markets.businessinsider.com

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

October 11, 2023 | finance.yahoo.com

H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)

October 10, 2023 | knoxdaily.com

Analysts: ZYNE stock price target of $1.25 in 12 months

October 5, 2023 | knoxdaily.com

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

October 4, 2023 | finance.yahoo.com

Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)

October 2, 2023 | knoxdaily.com

20 Countries With Highest Rate of Epilepsy

September 29, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

September 29, 2023 | finance.yahoo.com

Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal

September 27, 2023 | bizjournals.com

Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise

September 25, 2023 | knoxdaily.com

Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright

September 20, 2023 | knoxdaily.com

Negative sentiment towards ZYNE reflected in surge in short interest

September 15, 2023 | knoxdaily.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYNE, CRVS, AVIR, and VNDA Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.16 -0.05 (-1.56%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.22 +0.05 (+1.74%)

As of 06/13/2025 05:39 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$4.19 -0.05 (-1.18%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.23 +0.04 (+0.95%)

As of 06/13/2025 07:50 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.51 -0.12 (-2.59%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.65 +0.14 (+3.13%)

As of 06/13/2025 07:54 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Zynerba Pharmaceuticals NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time